Volume 28, Number 6—June 2022
Research
Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016
Table 3
Disease category |
No. participants |
Patient perspective, cost per participant,* 2016 US dollars |
|||||
Median |
Mean |
SD |
10th percentile |
90th percentile |
Range |
||
All† | 901 | 244 | 1,252 | 2,972 | 29 | 3,139 | 0–30,628 |
Confirmed localized | 402 | 170 | 1,070 | 4,164 | 27 | 2,535 | 1–26,686 |
Confirmed disseminated | 238 | 358 | 1,692 | 7,323 | 32 | 4,116 | 2–30,628 |
Probable | 261 | 315 | 1,277 | 4,629 | 34 | 3,987 | 0–18,833 |
*Cost per participant according to the patient perspective represents the sum of patient medical costs, nonmedical costs, cost of productivity losses, and other related costs as reported by each participant on all surveys. †Estimates for the overall population use the sample-weighted data except the range.
Page created: April 03, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.